International Journal of Epidemiology 2000;29:637-644
© International Epidemiological Association 2000
Risk factors for benign proliferative breast disease
a Division of Epidemiology, Prevention and Screening, Alberta Cancer Board, 1331–29 St NW, Calgary, Alberta, Canada, T2N 4N2. E-mail: chrisf{at}acb-epi.ucalgary.ca
b Tom Baker Cancer Centre, Alberta Cancer Board, Calgary, Alberta, Canada.
c Calgary Regional Health Authority, Calgary, Alberta, Canada.
d Cross Cancer Institute, Alberta Cancer Board, Edmonton, Alberta, Canada.
e Dynacare Kasper Medical Laboratories, Edmonton, Alberta, Canada.
f Vanderbilt University, Nashville, Tennessee, USA.
Background As part of a nested case-control study of benign proliferative breast disease (BPBD) conducted within the cohort of women participating in the Alberta breast screening programme, an analysis of all women who had a benign breast biopsy between 1990 and 1995 was undertaken to identify the epidemiological risk factors for BPBD.
Methods The breast biopsies of all eligible women were re-reviewed by a panel of four pathologists using Page's classification for benign breast disease. Cases were 165 women whose biopsies, upon review, showed benign breast tissue changes ranging from sclerosing adenosis to atypical ductal hyperplasia. Controls were 217 women whose biopsies showed no evidence of any proliferative or neoplastic changes. In-person interviews were conducted with all study subjects.
Results Women with 
25% fibroglandular breast tissue density, as compared to women with <25% density, experienced nearly a doubling in risk of BPBD (OR = 1.91, 95% CI : 1.24–2.94). All other possible risk factors examined were not associated with BPBD.
Conclusion This study suggests that fibroglandular tissue density may be a risk factor, or marker, for increased risk of BPBD.
Keywords Benign proliferative breast disease, risk factors, aetiology, screening
Accepted 7 February 2000
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. S. Menes, K. Kerlikowske, S. Jaffer, D. Seger, and D. L. Miglioretti Rates of Atypical Ductal Hyperplasia Have Declined with Less Use of Postmenopausal Hormone Treatment: Findings from the Breast Cancer Surveillance Consortium Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 2822 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Rohan, A. Negassa, R. T. Chlebowski, N. L. Lasser, A. McTiernan, R. S. Schenken, M. Ginsberg, S. Wassertheil-Smoller, and D. L. Page Estrogen plus Progestin and Risk of Benign Proliferative Breast Disease Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2337 - 2343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Rohan, A. Negassa, R. T. Chlebowski, L. Habel, A. McTiernan, M. Ginsberg, S. Wassertheil-Smoller, and D. L. Page Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial J Natl Cancer Inst, April 16, 2008; 100(8): 563 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Baer, S. J. Schnitt, J. L. Connolly, C. Byrne, W. C. Willett, B. Rosner, and G. A. Colditz Early Life Factors and Incidence of Proliferative Benign Breast Disease Cancer Epidemiol. Biomarkers Prev., December 1, 2005; 14(12): 2889 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Byrne, P. M. Webb, T. W. Jacobs, G. Peiro, S. J. Schnitt, J. L. Connolly, W. C. Willett, and G. A. Colditz Alcohol Consumption and Incidence of Benign Breast Disease Cancer Epidemiol. Biomarkers Prev., November 1, 2002; 11(11): 1369 - 1374. [Abstract] [Full Text] [PDF]
|
|